1. Home
  2. HSDT vs PTIX Comparison

HSDT vs PTIX Comparison

Compare HSDT & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSDT
  • PTIX
  • Stock Information
  • Founded
  • HSDT N/A
  • PTIX 1994
  • Country
  • HSDT United States
  • PTIX United States
  • Employees
  • HSDT N/A
  • PTIX N/A
  • Industry
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PTIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSDT Health Care
  • PTIX Health Care
  • Exchange
  • HSDT Nasdaq
  • PTIX Nasdaq
  • Market Cap
  • HSDT 106.2K
  • PTIX 2.0M
  • IPO Year
  • HSDT N/A
  • PTIX 2016
  • Fundamental
  • Price
  • HSDT $4.20
  • PTIX $3.13
  • Analyst Decision
  • HSDT Hold
  • PTIX
  • Analyst Count
  • HSDT 1
  • PTIX 0
  • Target Price
  • HSDT N/A
  • PTIX N/A
  • AVG Volume (30 Days)
  • HSDT 17.8K
  • PTIX 230.0K
  • Earning Date
  • HSDT 05-20-2025
  • PTIX 05-19-2025
  • Dividend Yield
  • HSDT N/A
  • PTIX N/A
  • EPS Growth
  • HSDT N/A
  • PTIX N/A
  • EPS
  • HSDT N/A
  • PTIX N/A
  • Revenue
  • HSDT $434,000.00
  • PTIX N/A
  • Revenue This Year
  • HSDT $0.04
  • PTIX N/A
  • Revenue Next Year
  • HSDT $75.10
  • PTIX N/A
  • P/E Ratio
  • HSDT N/A
  • PTIX N/A
  • Revenue Growth
  • HSDT N/A
  • PTIX N/A
  • 52 Week Low
  • HSDT $3.32
  • PTIX $2.51
  • 52 Week High
  • HSDT $27.45
  • PTIX $26.18
  • Technical
  • Relative Strength Index (RSI)
  • HSDT 41.92
  • PTIX 49.53
  • Support Level
  • HSDT $4.14
  • PTIX $2.35
  • Resistance Level
  • HSDT $5.02
  • PTIX $3.87
  • Average True Range (ATR)
  • HSDT 0.52
  • PTIX 0.47
  • MACD
  • HSDT 0.10
  • PTIX 0.05
  • Stochastic Oscillator
  • HSDT 44.36
  • PTIX 57.38

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: